Hikma Pharmaceuticals Plc Announcement (7220X)
November 28 2017 - 5:24AM
UK Regulatory
TIDMHIK
RNS Number : 7220X
Hikma Pharmaceuticals Plc
28 November 2017
Stock Exchange Announcement
For immediate release 28(th) November
2017
Hikma Pharmaceuticals Public Limited Company
(the "Issuer")
Re: Additional Guarantors of U.S.$500,000,000 4.250 per cent.
Guaranteed Notes due 2020
(ISIN: XS1213834978)
(the "Notes")
guaranteed by each of
Arab Pharmaceutical Manufacturing PSC
Eurohealth (USA), Inc.
Hikma Farmacêutica (Portugal) S.A.
Hikma Pharmaceuticals LLC and
West-Ward Pharmaceutical Corp.
(the "Initial Guarantors")
The Issuer refers to (i) the terms and conditions of the Notes
(the "Conditions") set out in the prospectus dated 8 April 2015
relating to the Notes and (ii) a deed of guarantee dated 10 April
2015 between the Issuer and the Initial Guarantors in favour of the
Holders and the Relevant Account Holders (each as defined therein)
(the "Deed of Guarantee").
Capitalised terms used in this Notice and not defined herein
shall have the meanings as set out in the Conditions and the Deed
of Guarantee.
NOTICE IS HEREBY GIVEN that, pursuant to and in compliance with
the provisions of Condition 5.7 (Guarantor Group) and the Deed of
Guarantee:
a) as of 21 August 2017, West-Ward Pharmaceuticals International
Limited has, pursuant to an accession deed of guarantee dated 21
August 2017 and an accession deed of covenant dated 21 August 2017,
become a Guarantor;
b) as of 29 April 2016, Roxane Laboratories, Inc. has, pursuant
to an accession deed of guarantee dated 29 April 2016 and an
accession deed of covenant dated 29 April 2016, become a Guarantor;
and
c) as of 29 April 2016, West-Ward Columbus Inc. has, pursuant to
an accession deed of guarantee dated 29 April 2016 and an accession
deed of covenant dated 29 April 2016, become a Guarantor.
West-Ward Pharmaceuticals International Limited, Roxane
Laboratories, Inc. and West-Ward Columbus Inc. are together "the
Additional Guarantors".
Each Additional Guarantor has agreed to:
a) perform and observe all obligations expressed to be
undertaken by a Guarantor under the Conditions, the Deed of
Guarantee, a deed of covenant between the Issuer and the Initial
Guarantors dated 10 April 2015 (the "Deed of Covenant") and a
fiscal agency agreement between, among others, the Issuer, the
Initial Guarantors and Citibank, N.A., London Branch dated 10 April
2015 (the "Fiscal Agency Agreement"), and each agrees that it shall
be bound by the Conditions, the Deed of Guarantee, the Deed of
Covenant and the Fiscal Agency Agreement in all respect as if it
had been an original party thereto; and
b) jointly and severally with all the Initial Guarantors,
unconditionally and irrevocably guarantee the payment of all sums
expressed to be payable by the Issuer in respect of the Notes to
the Holders and the Relevant Account Holders.
The following is the relevant information for the Additional
Guarantors:
Registered name: West-Ward Pharmaceuticals International
Limited
Place of incorporation: England and Wales
Date of incorporation: 23(rd) June 2011
Registered number: 07680243
Registered address: 1 New Burlington Place, London,
W1S 2HR
Ownership: The Additional Guarantor is a
wholly owned subsidiary of the
Issuer.
Registered name: West-Ward Columbus Inc.
Place of incorporation: Registered in the state of Delaware
Date of incorporation: 27(th) November 1978
Registered number: 863458
Registered address: 1809 Wilson Road
Columbus
OH 43228
United States
Ownership: The Additional Guarantor is a
wholly owned subsidiary of the
Issuer.
Registered name: Roxane Laboratories, Inc.
Place of incorporation: Registered in the state of Nevada
Date of incorporation: 14 February 2005
Registered number: E0034412005-8
Registered address: 1809 Wilson Road
Columbus
OH 43228
United States
Ownership: The Additional Guarantor is a
wholly owned subsidiary of the
Issuer.
Enquiries:
For enquiries or further information
please contact:
Peter Speirs
Company Secretary
Hikma Pharmaceuticals PLC
E-mail: peter@hikma.uk.com
This announcement has been issued through the Companies
Announcement Service of
The Irish Stock Exchange
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEOKFDDKBDDCDB
(END) Dow Jones Newswires
November 28, 2017 05:24 ET (10:24 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024